COMPARISON OF DIAGNOSTIC AND THERAPEUTIC DOSES OF I-131 LYM-1 IN PATIENTS WITH NON-HODGKINS-LYMPHOMA

Three patients with relapsed non-Hodgkin's lymphomas were given high d ose I-131-labeled LYM-1 murine anti-lymphoma antibody in a Phase I tri al. Each high dose infusion (65 mCi/m2) was preceded one week earlier by a tracer dose from which plasma pharmacokinetics were studied and d osimetry calculations were performed to predict doses to critical orga ns for the larger doses. None of the patients had definitive imaging o f known sites of lymphadenopathy following either the tracer or therap eutic doses. Two of the three patients had objective tumor regressions which lasted >16 weeks. One patient developed HAMA (human anti-mouse antibody) within five weeks and was not further exposed to LYM-1. Marr ow suppression proved to be the greatest toxicity.